📊 CRIS Key Takeaways
Investment Thesis
Curis is a pre-revenue stage biotech company burning substantial cash with negative stockholders' equity of -$14.7M, indicating the company has consumed more capital than it has raised. With only $8.3M in revenue against -$26.9M net income and -$20.8M operating cash outflow, the company faces severe financial distress and imminent liquidity crisis at current burn rates.
CRIS Strengths
- Modest revenue growth of 8.8% YoY shows some commercialization progress
- Positive cash position of $9.1M provides short-term runway
- No long-term debt reduces financing burden and bankruptcy risk from creditors
CRIS Risks
- Negative stockholders' equity of -$14.7M indicates shareholders have negative claim on assets
- Severe cash burn of -$20.8M operating cash flow with only $9.1M cash remaining (4.3 months runway)
- Operating losses of -$25.3M dwarf minimal $8.3M revenue, indicating unprofitable operations
- Current ratio of 0.70x signals inability to cover short-term obligations
- Negative free cash flow of -$250.8% FCF margin indicates unsustainable business model
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue growth trajectory and path to profitability timeline
- Changes in stockholders' equity and need for capital raises
CRIS Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CRIS Profitability Ratios
CRIS vs Healthcare Sector
How CURIS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CRIS Balance Sheet & Liquidity
CRIS 5-Year Financial Trend
5-Year Trend Summary: CURIS INC's revenue has shown modest growth of 1% over the 5-year period. The most recent EPS of $-8.96 indicates the company is currently unprofitable.
CRIS Growth Metrics (YoY)
CRIS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.9M | -$7.7M | $-0.49 |
| Q2 2025 | $2.5M | -$8.6M | $-0.68 |
| Q1 2025 | $2.1M | -$10.6M | $-1.25 |
| Q3 2024 | $2.8M | -$10.1M | $-1.70 |
| Q2 2024 | $2.2M | -$11.6M | $-2.03 |
| Q1 2024 | $2.1M | -$11.6M | $-2.05 |
| Q3 2023 | $2.8M | -$11.6M | $-2.13 |
| Q2 2023 | $2.2M | -$11.6M | $-0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CRIS Capital Allocation
CRIS SEC Filings
Access official SEC EDGAR filings for CURIS INC (CIK: 0001108205)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRIS
What is the AI rating for CRIS?
CURIS INC (CRIS) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRIS's key strengths?
Modest revenue growth of 8.8% YoY shows some commercialization progress. Positive cash position of $9.1M provides short-term runway.
What are the risks of investing in CRIS?
Negative stockholders' equity of -$14.7M indicates shareholders have negative claim on assets. Severe cash burn of -$20.8M operating cash flow with only $9.1M cash remaining (4.3 months runway).
What is CRIS's revenue and growth?
CURIS INC reported revenue of $8.3M.
Does CRIS pay dividends?
CURIS INC does not currently pay dividends.
Where can I find CRIS SEC filings?
Official SEC filings for CURIS INC (CIK: 0001108205) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRIS's EPS?
CURIS INC has a diluted EPS of $-2.19.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.